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Converting lead compounds into drug candidates is
a crucial step in drug development, requiring early
assessment of potency, selectivity, and off-target
effects. We have utilized activity-based chemical
proteomics to determine the potency and selectivity
of deubiquitylating enzyme (DUB) inhibitors in cell
culture models. Importantly, we characterized the
small molecule PR-619 as a broad-range DUB inhib-
itor, and P22077 as a USP7 inhibitor with potential
for further development as a chemotherapeutic agent
in cancer therapy. A striking accumulation of polyubi-
quitylated proteins was observed after both selective
and general inhibition of cellular DUB activity without
direct impairment of proteasomal proteolysis. The
repertoire of ubiquitylated substrates was analyzed
by tandem mass spectrometry, identifying distinct
subsets for general or specific inhibition of DUBs.
This enabled identification of previously unknown
functional links betweenUSP7 and enzymes involved
in DNA repair.
INTRODUCTION
Successful drug development within the ubiquitin proteasome
system (UPS) has enormous potential for the treatment of human
disease, but faces considerable challenges (Bedford et al.,
2011; Nalepa et al., 2006). These include the identification of
focused lead compounds, the development of suitable assays
for screening, and the availability of protein structures to aid
rational drug design once promising hits have been identified.
The need for selective inhibitors is exacerbated by the large
number of deubiquitylating enzymes (DUBs) (Reyes-Turcu
et al., 2009), ubiquitin conjugating enzymes (E2s), and ubiquitin
ligases (E3s) (Hua and Vierstra, 2011; Rotin and Kumar, 2009)
encoded by the human genome. Additional opportunities for
pharmacological intervention are provided by the discovery of
pathogen encoded factors that evolved to target the UPS of
the host cell, representing attractive targets for treatmentsChemistry & Biology 18, 1401–141against infectious diseases (Edelmann and Kessler, 2008; Isaac-
son and Ploegh, 2009; Lindner, 2007).
Activity-based proteomics has contributed substantially to our
understanding of the function of gene products (Cravatt et al.,
2008; Evans and Cravatt, 2006). Molecular probes specific for
the UPS allow tagging and detection of proteolytically active pro-
teasome subunits (Bogyo et al., 1998; Ovaa et al., 2003), active
deubiquitylating enzymes (DUBs) (Borodovsky et al., 2001,
2002) and ubiquitin-like (Ubl) specific proteases (reviewed in
Hemelaar et al. [2004] and Ovaa [2007]). Members of the ligation
machinery (E2s and E3s) are also detectable albeit with lower
efficiency compared to DUBs (Love et al., 2009). In addition,
the utility of activity-based ubiquitin-derived probes has been
exploited for structural studies of ubiquitin-bound DUBs
(Messick et al., 2008; Misaghi et al., 2005), in cell culture models
of disease allowing the detection of the active DUB population
(Sgorbissa et al., 2010), and for comparative tissue profiling
(Altun et al., 2010; Ovaa et al., 2004).
The UPS plays fundamental roles in the regulation of protein
turnover and function that are often altered in cancer progres-
sion, thereby providing entry points for the development of
anti-tumor chemotherapeutics (Bedford et al., 2011; Nalepa
et al., 2006). Targeting components of the ubiquitylation
machinerymay allow selectivemodulation of discrete substrates
mediated by the specificity of Ub ligation (E2 and E3 enzymes)
and deconjugation (DUBs) (Eldridge and O’Brien, 2010). Interfer-
ence with either arm of this pathway should allow highly targeted
pharmacological intervention, provided that compounds with
sufficient selectivity can be identified (Marblestone et al., 2010;
Nicholson et al., 2007; Sgorbissa et al., 2010).
Members of the DUB family that are known to contribute to
neoplastic transformation include USP1 (Fanconi Anemia),
USP2 (prostate cancer), DUB3 (stabilizing cyclin dependent
kinase 25A), USP4 (adenocarcinoma), USP7/USP10 (stabiliza-
tion of p53), USP9X (leukemias and myelomas), and BRCC36
(Hussain et al., 2009; Nijman et al., 2005; Pereg et al., 2010;
Reyes-Turcu et al., 2009; Schwickart et al., 2010). In addition,
mutations in the gene encoding the DUB CYLD can lead to the
neoplastic condition Cylindromatosis, whereas other DUBs are
expressed at lower levels in cancer including A20 (B cell and
T cell lymphomas) and BAP1 (brain, lung, and testicular cancers)
(Hussain et al., 2009).2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1401
AB
Figure 1. Structures of DUB Inhibitors PR-619 and P22077 and In Vitro DUB Inhibition Profiles
(A) Molecular structures of PR-619 and P22077.
(B) Inhibition profiles of PR-619 (green bars) and P22077 (orange bars) using a panel of DUBs, UBL-specific, cysteine, and other proteases as determined in the
Ub-PLA2 assay (Nicholson et al., 2008). USP5 and USP47 inhibition was assayed using Ub-EKL, and UCH-L1 and UCH-L3 inhibition with Ub-Rh110. Other
cysteine proteases and other noncysteine proteases were assayed as described in the Experimental Procedures. VIndicates autofluorescence. #Represents
EC50 values equal or larger than 5 3 10
5 [M]. Mean values and standard deviations from three or more independent experiments are shown. PLA2, phos-
pholipase A2; USPs, ubiquitin-specific proteases; JOSD2, Josephin domain containing 2; UCH-Ls, ubiquitin C-terminal hydrolases; DEN1, deneddylase 1; PLpro,
SARS-Co virus papain-like protease; SENP6, Sentrin-specific protease 6; CT-L, chymotryptic-like, 20S proteasome; MMP13, metalloproteinase 13. See also
Figures S5 and S6 and Table S1.
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Activity-Based MS for Profiling DUB InhibitorsUSP7, also known as HAUSP, has been found to be critical in
cancer progression due to its influence on the stability of the
tumor suppressor p53 (Cheon and Baek, 2006; Colland, 2010;
Nicholson et al., 2007). USP7 preferentially deubiquitylates the
E3 ligase HDM2 and its binding partner HDMX as well as their
substrate p53 (Brooks et al., 2007; Cummins and Vogelstein,
2004; Li et al., 2002, 2004; Meulmeester et al., 2005). Like most
E3s, HDM2 has the capacity to auto-ubiquitylate and promote
its own degradation. The cellular consequence of stabilizing
HDM2 is the polyubiquitylation and subsequent degradation of
p53. Thus inhibition of USP7 is predicted to destabilize HDM2
and stabilize p53. Additional substrates of USP7 have been
reported including claspin, FOXO4, and PTEN (Faustrup et al.,
2009; Song et al., 2008; van der Horst et al., 2006). Therefore
USP7 exerts both p53-dependent and p53-independent effects
on controlling cell proliferation and apoptosis, making USP7 an
attractive target for pharmacological intervention in cancer
(Colland et al., 2009; Goldenberg et al., 2008; Hussain et al.,
2009;Nicholson et al., 2007;Nicholson andSureshKumar, 2011).
In an effort to identify small molecule inhibitors of USP7, two
compounds that inhibit USP7 in the low mM range were identified
using the Ub-CHOP reporter based screening assay (Golden-
berg et al., 2008; Nicholson et al., 2008). The potency and selec-1402 Chemistry & Biology 18, 1401–1412, November 23, 2011 ª2011tivity of these molecules was evaluated in vitro and in living cells
using an activity-based chemical proteomics approach. In this
competition assay format, drug selectivity and potency was
assessed in a straightforward manner using immunoblotting as
readout. Further quantitative data were obtained by anti-HA
immunoprecipitation after active site labeling with a HA-tagged
DUB-specific molecular probe and quantitative mass spectro-
metry. In this way, P22077 was shown to inhibit USP7 functions
in cells. In contrast, PR-619 was found to be a broad inhibitor
of DUB activity. Moreover, our experiments demonstrate that
DUB inhibitors with differing specificities induce the accumula-
tion of polyubiquitylatedproteins in cellswithout directly affecting
proteasome activity. These results provide novel insights into
DUB-associated proteins and pathways.
RESULTS
A robust in vitro assay that has been validated for high
throughput screening applications (Ub-CHOP reporter system
[Goldenberg et al., 2008; Nicholson et al., 2008]) was employed
to sample a small molecule diversity based library for modulators
of USP7 activity. Two of the confirmed hits from this screen were
PR-619 (2,6-diaminopyridine-3,5-bis(thiocyanate)) (Figure 1A)Elsevier Ltd All rights reserved
AB
Figure 2. Small Molecule Inhibitors Affect DUBs in Living Cells
The inhibitors PR-619 and P22077 were incubated with HEK293T cells for 6 hr at concentrations of 5, 10, 20, or 50 mM. DMSO (0.1%) was used in control lanes.
(A) Crude cell extracts were labeled with HAUbVME or HAUbBr2 for 30 min at 37C prior to separation by 4%–12% Bis-tris SDS-PAGE and immunoblotting with
HA, USP7, and b-actin (loading control) antibodies. + and – indicates USP7 in a free form () or labeled with HA-UbVME or HA-UbBr2 (+), respectively.
(B) Input loading controls of extracts prepared from inhibitor treated cells showing equal USP7 and b-actin levels by immunoblotting. See also Figures S1, S5,
and S6.
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P5091 selectively inhibited USP7 relative to other DUBs and
other families of proteases, and subsequent medicinal chemistry
optimization generated additional analogs including P22077
(1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone)
(Figure 1A) (Tian et al., 2011). The inhibitory activities of P22077
and PR-619 were compared in vitro against a panel of DUBs,
cysteine proteases, and other families of proteolytic enzymes.
Data from these studies demonstrate that P22077 inhibits
USP7 and the closely related DUB USP47 (Figure 1B; see Table
S1 available online). In contrast, PR-619 exhibits a broader inhib-
itory profile targeting multiple DUBs, but with limited activity
against other families of proteases, including representative
examples of other families of cysteine proteases (Figure 1B;
Table S1).
To address the effects of these compounds in a cellular
context, DUB inhibitory capacities of PR-619 and P22077 were
tested in crude cell extracts. To this end, a competition assay
was performed against the DUB active site probes HA-UbBr2
and HA-UbVME (Borodovsky et al., 2002; Hemelaar et al.,
2004). Human embryo kidney (HEK293T) cell extracts were
incubated with increasing concentrations of PR-619 or P22077
followed by labeling with HA-UbBr2 or HA-UbVME to profile
residual DUB activity (Figure S1). The identification of DUBs
by immunoblotting was based on molecular weights of known
DUBs, a comparison with labeling patterns from previous
studies (Borodovsky et al., 2002; Hemelaar et al., 2004) and iden-
tification by mass spectrometry as shown below. CompoundChemistry & Biology 18, 1401–141PR-619 inhibited the majority of DUBs labeled by HA-UbBr2
and HA-UbVME at a concentration of 20 mM, and to a lesser
extent at 5 mM (Figure S1A). In contrast, compound P22077
inhibited a much smaller subset of DUBs at a concentration of
15–45 mM (Figure S1B). This indicated overlapping binding of
the two compounds and the ubiquitin-based probes, and
a greater selectivity of P22077 over PR-619 in targeting DUBs.
Both compounds inhibited probe binding to USP7 in the low
micromolar range.
Having established the inhibition profiles of cellular DUBs
upon treatment with PR-619 and P22077 in cell lysates, experi-
ments on living cells were conducted. Concentration ranges
for the inhibitors were determined by cytotoxicity assays that
were performed in HCT-116 colorectal cancer and HEK293T
cells. Data from these studies demonstrated that P22077 and
PR-619 induce (tumor) cell death with EC50 values in the low
micromolar range (Figures S2A and S2B).
Cell permeability and the potency of DUB inhibition in living
cells were addressed in another set of experiments. This
involved incubation of HEK293T cells with PR-619 or P22077,
followed by lysis, labeling with HA-UbVME or HA-UbBr2 and
immunoblotting analysis (Figure 2). PR-619 interfered with probe
labeling at concentrations of 5 mM and higher (Figure 2A). As
observed previously, P22077 at 20 mM did not have any notable
effect on the overall active site profiling with the HA-tagged
probes and affected only a subset of DUBs at 50 mM. However,
USP7 labeling was partially inhibited at 20 mMP22077, and com-
plete inhibition was observed at 50 mM or higher concentrations.2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1403
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Activity-Based MS for Profiling DUB InhibitorsFigure 2B shows USP7 protein input levels at all inhibitor
concentrations tested. PR-619 also inhibited labeling of USP7
by the probes, but at the same time targeted many other DUBs
within the same concentration range, consistent with its broader
inhibitory profile.
Exposure of inhibitor—treated cell lysates to the HA-Ub—
probes, which typically bind covalently and irreversibly to active
DUBs, may result not only in labeling of residual DUB activity but
also in gradual replacement of the reversible inhibitors from the
enzyme’s active sites. In addition, the HA-Ub probesmay prefer-
entially label a subset of DUBs that may also modulate such
a read out. These parameters may influence the inhibition
profiles obtained from such assays. To address the HA-Ub
probe’s preferences for DUBs, HEK293T cell extracts were incu-
bated with different amounts of HA-UbBr2 or HA-UbVME, or at
a fixed concentration for different times (Figure 3A). Both probes
appear to label UCH-L3, USP5/16, and USP9/24 most effi-
ciently, and HA-UbBr2 preferentially targets OTUB1. However,
upon prolonged incubation, the labeling profile becomes more
complex (Figure 3A). To test whether under these circumstances
reversibility with the small compounds may occur, we incubated
PR-619 and P22077 with HEK293T cell lysates prior to labeling
with different concentrations of HA-UbVME or HA-UbBr2 for
various length of time (Figures 3B and 3C). In both cases, inhibi-
tion by the small molecule compounds persisted even after
labeling with the Ub-probes for >2 hr (Figures 3B and 3C). The
effect of inhibition varied between the different DUBs due to
different affinities of the compounds but also the Ub-probes
themselves as described for Figure 3A. Furthermore, little to
no displacement was observed, in particular for USP7 and
P22077 under the experimental conditions used (Figure 3C).
Although profiling experiments using ubiquitin-based active
site-directed probes gave an insight into the DUBs targeted by
P22077 and PR-619 in living cells, immunoblotting did not
provide sufficient information to distinguish between all the
different USPs, as many of them have similar molecular weights,
in particular in the 100–150 kDa range. We therefore developed
an activity-based quantitative proteomics approach to over-
come this problem. In this method, HEK293T cells were treated
with DMSO or 25 mM concentrations of PR-619 or P22077 for
6 hr prior to cell lysis and labeling with HA-UbBr2 or HA-UbVME
(Figure 4A). DUBs were thereby labeled differentially depending
on the inhibition profile of the tested inhibitor. DUB-HA-Ub-
probe adducts were immunoprecipitated with anti-HA beads
and eluted material subjected to in-solution trypsin digestion.
The samples were then analyzed in triplicate by label-free quan-
titative mass spectrometry (MS) using nano-UPLC-MS/MS,
resulting in a differential display of active DUBs in inhibitor
treated relative to control cells. Two independent experiments
were conducted, and we identified 49 DUBs, among which 34
were pulled down using the HA-UbBr2 probe and 48 with the
HA-UbVME probe (33 DUBs were identified with both probes
(Figure 4B; Table S2; data not shown). For 25 of the DUBs iden-Figure 3. Dynamics and Specificity of Activity-Based DUB Profiling in
HEK293T cells were treated either with (A) DMSO, (B) 25 mM PR-619, or (C) 25 m
increasing concentrations of HA-UbBr2 or HA-UbVME active site probes (left two
separated by 4%–12%Bis-tris SDS-PAGE and analyzed by immunoblotting with H
S6.
Chemistry & Biology 18, 1401–141tified, relative quantitative information was obtained, indicating
different degrees of specificity for the inhibitors PR-619 and
P22077 (Figure 4B). As expected, PR-619 showed a much
broader inhibitory profile as compared to P22077, which mainly
targeted USP7, but also USP47 when tested at 25 mM (Fig-
ure 4B). The differential targeting of DUBs between the two
inhibitors is also reflected in the immunoblotting profiles after
enzyme capture with the HA-UbVME probe, which was less
efficient in the presence of PR619 as compared to DMSO or
P22077 (Figure 4C). Furthermore, the inhibition profiles observed
by quantitative mass spectrometry were further validated for
a subset of DUBs by immunoblotting with antibodies specific
for USP9, USP47, USP7, USP15, USP5, USP14, OTUB1,
UCH-L3, and UCH-L1 (Figure 5). Inhibition of a particular DUB
was indicated by interfering with the mass shift provoked by
labeling with HA-UbBr2 or HA-UbVME (indicated with + and ,
Figure 5). USP7 labeling by HA-UbBr2 and HA-UbVME was
partially impaired in the presence of PR-619 and P22077,
whereas all other DUBs tested were essentially unaffected by
25 mM P22077 with the exception of USP47 when labeled with
HA-UbBr2. Labeling of all DUBs by both probes was affected
partially by 25 mM and fully by 50 mM PR-619. In addition to the
ones validated by immunoblotting in Figure 5, MS analysis
revealed that PR-619 also interfered with labeling of USP1, 4,
8, 10, 16, 19, 22, 24, 28, 48, VCIP135, OTUD5, BAP1, ATXN3,
YOD1, and UCH-L5 (Figure 4B).
Having demonstrated the DUB inhibitory profiles of PR-619
and P22077 in living cells, we explored the effect of these inhib-
itors on the homeostasis of polyubiquitylated material. This may
provide an entry point for identifying substrate candidates for
DUBs targeted by these compounds, and offers valuable infor-
mation on the cellular effects of these inhibitors. To this end,
HEK293T cells were treated with PR-619 or P22077 for 0.5 up
to 20 hr or at different doses followed by cell lysis and anti-
ubiquitin immunoblotting. Interestingly, treatment of cells with
PR-619 as well as P22077 led to the accumulation of polyubiqui-
tylated material in a dose- and time-dependent fashion (Figures
6A and 6B). In the case of PR-619, incubation times of >6 hr
or >50 mM led to loss of cell material likely due to toxicity (Fig-
ure 6B). This effect was not due to direct inhibition of the
proteolytic activity of the proteasome as shown by competitive
labeling of the active proteasome b-subunits and in vitro enzyme
activity assays (Figure 1B; Figure S3, and Table S1). To shed
further light on the nature and type of ubiquitylated proteins
that accumulated upon exposure to inhibitors, polyubiquitylated
material was isolated from cells usingGST-TUBEs (tetraubiquitin
binding entities) (Figure 6C). We used TUBE1 and TUBE2 that
possess a high binding affinity for K48- and K63-polyubiquitin
chains (Hjerpe et al., 2009). A varying amount of ubiquitylated
protein material was observed when cells were exposed
to 0.1% DMSO, 25 mM PR-619, or 25 mM P22077, indicating
differences in ubiquitylated proteins that were accumulating.
We subjected eluted material from TUBE1 and TUBE2 affinityCells
M P22077 for 6 hr at 37C. Crude extracts were prepared and incubated with
panels) or 2 mg of probe for the indicated times (right two panels). Samples were
A, USP7, and b-actin (loading control) antibodies. See also Figures S1, S5, and
2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1405
A B
C
Figure 4. DUB Inhibition Profile in Living Cells Revealed by Activity-Based Quantitative Mass Spectrometry
(A) HEK293T cells were treated with 25 mMPR-619 or 25 mMP22077 for 6 hr. Crude extracts were incubated with either HAUbVME or with HAUbBr2 followed by
anti-HA immunoprecipitation. Eluted material was digested with trypsin and subjected to label-free quantitative mass spectrometry (UPLC-MS/MS) analysis.
(B) Inhibition profiles of 25 DUBs identified by tandem mass spectrometry (UPLC-MS/MS). Relative abundance ratios of inhibition based on DUBs isolated from
cells treated with PR-619 (green bars) or P22077 (orange bars) as compared to controls. Top panel: unique DUBs isolated using the HA-UbBr2 probe. Bottom
panel: DUBs isolated using the HA-UbVME probe. The abundance of each DUB is based on the ion intensities of tryptic peptides matching a unique DUB protein
sequence identified in triplicate analytical runs. Analysis of variance (ANOVA) was used to calculate the statistical significance of the observed changes: *p < 0.05,
**p < 0.01, ***p < 0.001 (see Supplemental Information). One of two independent experiments is shown.
(C) As described above, cellular DUBs were isolated by HA-UbVME labeling and anti-HA immunoprecipitation. As a control for the MS experiment (B), input (left
panel), and anti-HA immunoprecipitated material were separated by 4%–12% Bis-tris SDS-PAGE and analyzed by immunoblotting with HA, USP7, and b-actin
(loading control) antibodies. See also Figure S5 and Table S2.
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Figure 5. Inhibition of SelectedDUBs by P22077 and PR-619 in Living
Cells Detected by Activity-Profiling and Immunoblotting
HEK293T cells were treated with DMSO (lane 2), PR-619 (25 and 50 mM, lanes
3/4), P22077 (25 and 50 mM, lanes 5/6), or MG-132 (10 mM, lane 7) for 6 hr,
followed by cell lysis and labeling with HAUbVME or HAUbBr2 (lane 1 is lysate
alone). Samples were separated by 4%–12% Bis-Tris SDS-PAGE and
analyzed using HA-, USP5-, USP7-, USP9-, -USP14, -USP15, -USP47,
-OTUB1, -UCH-L1, and -UCH-L3 antibodies. b-actin was used as a loading
control. See also Figures S5 and S6.
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ysis by tandem mass spectrometry (Figure 6G; Table S3). This
revealed relative quantitative information on 232 proteins (Fig-
ure 6G; Table S3). Ubiquitin was found not only as lys48-linked,
but also as lys63, lys11 and lys6-linked poly-Ub chains in
untreated, but also cells treated with PR-619 and P22077
(Figures 6D–6F). No evidence for the presence of lys27-, lys29-,
and lys33-linked poly Ub-chains was found. Isotopically labeled
peptide standards representing Ub derived tryptic fragments
with lys(gly-gly) tags were used to quantitate the degree of
Ub-linkages detected in cell extracts (Figure 6E, see also
Supplemental Experimental Procedures). Interestingly, PR-619Chemistry & Biology 18, 1401–141inhibition resulted in an accumulation of K48- and K63-, whereas
P22077 exposure led to enrichment of mainly K48-linked poly-Ub
chains (Figure 6F). Components of the 26S proteasome complex
were also accumulated when cells were exposed to either
inhibitor (Figure 6G). P22077 inhibition exhibited changes in
ubiquitylated protein levels that were distinct from the broad
specificity inhibitor. Proteins observed at differential abundance
in control as compared to P22077-treated cells could represent
either direct or indirect substrates of the DUBs targeted by
this inhibitor (mostly USP7 and probably USP47 under these
circumstances).
To provide experimental evidence for this, we examined the
fate of the well known USP7 target, HDM2, upon pharmacolog-
ical inhibition of USP7 with P22077 (Figure 7). HDM2 levels
decreased initially after 2 hr of treatment as expected when not
deubiquitylated by USP7 (Figure 7A; Figures S4A and S4B), in
line with independent studies in USP7/ cells (Cummins et al.,
2004; Meulmeester et al., 2005). p53 protein and its transcrip-
tional target p21 accumulated after 8 hr of treatment (Figure 7A;
Figures S4A and S4B), consistent with previous studies in which
USP7 levels were ablated (Li et al., 2004). The increase in p53
protein induces a feedback mechanism that stimulates addi-
tional HDM2 (Vogelstein et al., 2000). Subsequently, p53 levels
drop again (likely due to the elevated HDM2).
As an additional confirmation that P22077 is directly inhibiting
USP7 we also determined the ability of P22077 to destabilize
claspin, a scaffolding protein required for Ataxia telangiectasia
and Rad3 related (ATR) mediated phosphorylation of the check-
point kinase Chk1 and that is subject to ubiquitin dependent
proteasomal degradation (Faustrup et al., 2009; Kumagai and
Dunphy, 2000; Mailand et al., 2006). In agreement with published
reports, P22077 treatment of U2OS cells during release from
G1/S arrest induced with hydroxyurea resulted in a dose-depen-
dent loss of claspin protein and a concomitant decrease in
phospho Serine 317 Chk1 (Figure 7B). Furthermore, quantitative
MS suggested the E3 ubiquitin ligase components RBX1,
DCAF7, DCAF11, and the DNA damage binding protein 1
(DDB1) to be reduced upon cellular treatment with P22077 (Fig-
ure 6G; Table S3). A reduction in DDB1 protein levels was
confirmed by immunoblotting (Figure 7C). To test whether this
was due to incapacitation of USP7 or other DUBs, USP7,
USP47, and USP15 were knocked down and the levels of
DDB1 assessed under these conditions. Consistent with the
P22077 data, DDB1 levels were only reduced when USP7 was
knocked down (Figures 7D and 7E).
DISCUSSION
Recent studies have uncovered a range of small molecules with
inhibitory activity against DUBs such asUCH-L1 (Liu et al., 2003),
PLpro (Ratia et al., 2008), and USP7 (Colland et al., 2009; Tian
et al., 2011). Testing specificity and selectivity of small molecular
compounds toward DUBs is challenging, and is in most cases
performed in vitro using a panel of recombinant proteolytic
enzymes in enzymatic assays. Alternatively, genetically engi-
neered substrates for enzymes taggedwith fluorescent reporters
can be generated recombinantly or expressed in cells and used
as readouts for specific enzyme (DUB) activities (Nicholson et al.,
2008; Shanmugham and Ovaa, 2008). However, this only2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1407
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Figure 6. General and Specific DUB Inhibition Lead to Accumulation of Polyubiquitylated Proteins
(A) HEK293T cells were treated with PR-619 or P22077 for 2 hr at the indicated concentrations or 10 mM Z-Leu-Leu-Leu-vinyl sulfone (ZL3VS) as a control for
proteasome inhibition, and cell lysates analyzed by 4%–12% bis-tris SDS-PAGE and anti-ubiquitin immunoblotting. b-actin was used as a loading control.
(B and C) HEK293T cells were treated with 0.1%DMSO, (B) 50 mMPR-619, or (C) 50 mMP22077 for the indicated length of time and analyzed as indicated above.
(D) HEK293T cells were treated for 6 hr with 0.1% DMSO (lane 1), 25 mM PR-619 (lane 2), or 25 mM P22077 (lane 3) followed by cell lysis and coimmunopre-
cipitation of polyubiquitylated material using GST-tagged tetraubiquitin binding entities 1 (TUBE1/T1) or TUBE2 (T2). Input, flow-through and TUBE1 and 2 eluted
material was analyzed by 4%–12% bis-tris SDS-PAGE and anti-ubiquitin immunoblotting. b-actin was used as a loading control.
(E and F) Analysis of poly-Ub linkages by mass spectrometry. One hundred femtomoles of K48-, K6-, K11-, and K63-linked Gly-Gly containing standard peptides
were separated by UPLC and analyzed by MS. Ion peak intensities were used as correction factors to calculate the percentage [%] of different poly-Ub linkages
enriched with TUBE1 and 2 (F) and after treatment either with DMSO, PR-619, or P22077 (see also Supplemental Information).
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least 550 proteases encoded by the human genome that repre-
sents a challenging task (Puente et al., 2003). Furthermore,
a large proportion of the DUB family exhibit isopeptidase activity,
potentially reducing the usefulness of genetically encoded
substrates.
We utilized the ubiquitin-based active site probes HA-UbVME
and HA-UbBr2 that were previously demonstrated to target
a broad range of DUBs with no detectable cross-reactivity to
other proteolytic enzymes (Borodovsky et al., 2002; Hemelaar
et al., 2004). This can be used as an enrichment step to isolate
active DUBs following previous inhibitor treatment of cells or
crude extracts, providing a ‘‘competition profile’’ of the inhibi-
tors that can be visualized by immunoblotting or characterized
by quantitative tandem mass spectrometry. The latter allowed
measuring 49 DUBs by UPLC-MS/MS, representing half of
all currently known human DUBs (Figure 4; Table S2). These
results indicated the broad inhibitory nature of PR-619 and the
more selective properties of P22077 toward USP7, and these
are particularly relevant as this is within the physiological
context of endogenous DUBs (Figures 4 and 5). The best selec-
tivity of P22077 was observed when cells were treated with
20 mM P22077, with a cross-reactive effect against USP47 (Fig-
ure 4B and in part in Figure 5). This was consistent with the inhi-
bition profiles observed when tested against recombinant
enzymes (Figure 1B; Table S1). USP7 and USP47 share consid-
erable homology (Parsons et al., 2011) and may therefore be
susceptible to inhibition by the same small molecule. UCH-L5
was affected when cell extracts were treated with P22077 (Fig-
ure S1), although this was not the case in cell based experi-
ments (Figures 2, 3, 4, and 5) nor with recombinant enzyme
(Figure 1B). This discrepancy may result from an association/
dissociation of UCH-L5 from the proteasome complex that
may affect activity, which might be altered upon the preparation
of cell extracts. Although selectivity against USP7 may be
required for a maximal therapeutic effect in anti-cancer treat-
ments, rigorous testing will reveal whether a certain degree of
cross-reactivity to other DUBs could be beneficial or cause
unwanted side-effects.
To gain further insights into how selective inhibition of DUBs in
cells can affect intracellular processes, a proteomics analysis of
polyubiquitylated material that accumulated after inhibitor treat-
ment of HEK293T cells was performed. The use of tetraubiquitin
binding entities (TUBEs 1and 2) enriched formainly K48- and K63-
linked polyubiquitylated material as detected by tandem mass
spectrometry (Hjerpe et al., 2009). Treatment with both inhibitors
led to the accumulation of mainly K48-linked poly-Ub material
(Figures 6E and 6F). TUBE1 and 2 both have nanomolar affinities
for K48- and K63- linked poly-Ub chains, so it may be feasible that
other chain linkages were isolated indirectly as part of branched
Ub structures (Kim et al., 2007). Broad DUB inhibition by PR-619
as well as interference with mainly USP7 by P22077 resulted in
an accumulation of 26S proteasome complexes (Figure 6G;(G) Differentially ubiquitylated proteins present in cells treated with DUB inh
Q16186,O00231,O00232,P28074, A8K3Z3,Q99436,O75832,O75832, O43242, p
RAD23; TUBE2: UBA derived from Ubiquilin (Hjerpe et al., 2009). cRatio determi
peptides assigned to proteins (see Supplemental Information). dAnalysis of varianc
Figures S3, S5 and S6 and Table S3.
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teasome at the concentrations employed (Figure 1B; Figure S3,
and Table S1). However, a general accumulation of high molec-
ular weight polyubiquitylated material was observed (Figure 6).
This observation may be explained by a potential ‘‘overload’’ of
proteasomal proteolysis capacity with accumulated polyubiqui-
tylatedmaterial binding to subunits of the 19S complex, resulting
in co-isolating 26S proteasomes using TUBEs. Despite the more
selective nature of P22077 relative to PR-619, we observed an
accumulation of polyubiquitylated material when cells were
treated with either of these inhibitors (Figure 6). To address
whether the incapacitation of a single DUB, such as USP7, can
lead to poly-Ub accumulation, we used siRNA knockdown
experiments. Interestingly, we detected no noticeable increase
in poly- and monoubiquitin material (data not shown). The
discrepancy between the pharmacological inhibition and siRNA
based reduced expression may result from the fact that a knock-
down leads to the disappearance of the entire protein, whereas
the inhibitor inactivates the enzyme. Also, a knockdown occurs
in a time frame of 48–72 hr, leading to compensatory mecha-
nisms for the turnover of poly-Ub material not seen upon acute
inhibitor treatment (2–6 hr). Alternatively, P22077may also inhibit
other DUBs not assayed in this study. Inhibition with PR-619
and P22077 led to the enrichment of a number of E3 ubiquitin
ligases/ligase components including UBR5, AMFR, RNF126,
RNF25, RNF214, and Cullin 3, whereas the E3 ligases/ligase
components HECTD3, RBX1, and Cullin 1 were reduced (Fig-
ure 6G; Table S3). The ubiquitylation and turnover of potential
substrates (such as E3 ligases) or subsequent processes depen-
dent onDUBs are expected to be increased uponDUB inhibition,
leading to their disappearance when compared to untreated
controls. The occurrence of both accumulation and reduction
in protein levels is currently unexplained, but could be due to
a selective degradation of short-lived, and an accumulation of
long-lived (ubiquitylated) proteins that may be aggravated
upon DUB inhibition. Alternatively, inhibition of DUBs involved
in the stabilization of E3 ligases can lead to indirect accelerated
turn-over of substrates (including other E3 ligases) or vice versa,
thereby complicating the picture of proteins that are affected
by the pharmacological intervention of deubiquitylation. Consis-
tent with the notion that P22077 predominantly inhibits USP7, we
noted altered levels of HDM2, p53 and p21 upon treatment of
cells with P22077 (Figure 7A; Table S3). The initial decrease in
HDM2 after 2 hr followed by an increase in p53 and its transcrip-
tional target p21 are consistent with previous reports (Cummins
and Vogelstein, 2004; Li et al., 2004). The increase in HDM2
after 8 hr of treatment is likely due to the feedback loop between
p53 and HDM2 (Vogelstein et al., 2000). Also, claspin, a scaf-
folding protein stabilized by USP7 that is involved in regulating
the Chk1 kinase activated during the DNA damage response
(Faustrup et al., 2009), is destabilized upon cellular treatment
with P22077 (Figure 7B), providing further confidence that
USP7 is one of the main pharmacological targets in cells.ibitors identified by tandem mass spectrometry. aP35998,P62333,O00487,
< 0.01. bTUBE: tetra-ubiquitin binding entities; TUBE1: UBA derived from
ned using LC-Progenesis software, based on the mass peak ion intensities of
e (ANOVA) for assessing the significance of changes in ratio (p < 0.05). See also
2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1409
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Figure 7. P22077 Affects USP7 Targets and DDB1 in Cells
(A) Treatment of HCT116 cells with 25 mMof the selective inhibitor P22077, but
not with 0.1% DMSO, leads to increased levels of HDM2, p53 and p21. One
representative out of three independent experiments is shown. See also Fig-
ure S4.
(B) U2OS cells were treated with hydroxyurea (HU) to synchronize them, prior
to incubation with the indicated concentrations of P22077 for 8 hr (AS, asyn-
chronous cells). Cells were lysed and extracts separated by SDS-PAGE fol-
lowed by immunoblotting analysis using claspin, phospho-317-Chk1, Chk1,
and b-actin antibodies.
(C) HEK293T cells were treated with DMSO or 25 mM P22077 for the indicated
times. Crude cell extracts were then separated by SDS-PAGE and analyzed by
anti-DDB1 immunoblotting.
(D and E) HEK293T cells were transfected with siRNAi specific for USP7,
USP15, or USP47 for 72 hr as described in Supplemental Experimental
Procedures. Crude cell extracts were separated by SDS-PAGE and analyzed
by immunoblotting using DDB1, USP7, USP15, USP47, and b-actin anti-
bodies. See also Figures S3, S4, S5, and S6.
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protein DDB1, RBX1, DCAF7 and DCAF11, all of which are
subunits of E3 ubiquitin ligases (Hu et al., 2004), indicating that1410 Chemistry & Biology 18, 1401–1412, November 23, 2011 ª2011USP7may be involved in altering the stability of such complexes.
As a validation of the proteomic screen data we demonstrated
that USP7, but not USP15 or USP47 knockdown led to a
decrease in DDB1 protein levels (Figure 7C). A connection
between USP7 with the DNA damage response has been
described, possibly via histone deubiquitylation (Khoronenkova
et al., 2011), and is further strengthened by its ability to stabilize
claspin, a protein necessary for Chk1 mediated cell cycle arrest
following DNA damage (Faustrup et al., 2009; Scrima et al.,
2011). Potentially, these findings could be exploited clinically
by developing a synergistic therapeutic approach consisting
of inhibition of USP7 to ablate the G2/M checkpoint in combina-
tion with a genotoxic agent, resulting in more efficient cancer
therapies.
SIGNIFICANCE
Novel approaches to screen small molecule inhibitors in
their natural environment within the cell are of major impor-
tance to elucidate inhibitor selectivity and specificity. Here
we demonstrate a powerful chemistry-based functional pro-
teomics and mass spectrometry method for screening DUB
inhibition in living cells. Using an inhibitor with selectivity for
USP7, we describe a possible link between this DUB and
aspects of the DNA damage response, which may have
implications for novel combinatorial anticancer therapies.
In general, this novel approach permits the determination
of inhibitor profiles against endogenous DUB levels in
cells/tissues under healthy and pathological circumstances,
and can be adopted for the drug screening processes in
biotech, pharma, and academia at an advanced stage to
further select promising lead compounds. Additional advan-
tages include the ability to confirm the cellular permeability
of inhibitors and examine compounds that cannot be tested
for enzyme inhibition due to autofluorescent properties.
Cell-based assays with an active-site probe readout for
direct measurement can also be applied to other enzyme
classes, and can be multiplexed using several probes with
different tags, which may uncover a wider range of target
leads and more than one enzyme species affected by the
compound. Specific and promising small molecules discov-
ered by a combination of high throughput screening and
cell-based MS profiling as described in this study can be
used as lead compounds for disease treatment, but also
as research tools to understand the underlying mechanisms
of the biology of targeted enzymes.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
HEK293T and HeLa cells were grown in DMEM medium supplemented with
10% FCS, 1% penicillin, and 1% Glutamax at 37C in the presence of 5%
CO2. HCT116 and U2OS cells were grown in DMEM, 10% FBS, 1% P/S, and
2 mM glutamine (5% CO2). Chemicals were purchased from Sigma-Aldrich
unless indicated otherwise. The following antibodies were used: anti-OTUB1
(Edelmann et al., 2010), anti-USP5 (Lifesensors, PA), anti-USP7 (Bethyl Labo-
ratories, TX), anti-USP9, anti-USP14, anti-UCH-L1, anti-UCH-L3, anti-HDM2,
and anti-USP47 (Santa Cruz Biotechnology, CA), anti-b actin,-tubulin (Sigma),
anti-USP15 (Bethyl Laboratories), anti-p53 (Calbiochem), anti-p21 (Cell
Signaling), anti-Claspin (Bethyl), phospho-Chk1Ser317, and anti-Chk1 (Cell
Signaling).Elsevier Ltd All rights reserved
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Activity-Based MS for Profiling DUB InhibitorsCharacterization of the Inhibitors PR-619 and P22077
The synthesis and analysis of PR-619 (Beer et al., 2002) and P22077 are
described in detail in Supplemental Experimental Procedures and Figures
S5 and S6.
In Vitro Enzyme Assays
Recombinant full length USP7, USP2 core, USP5, JOSD2, DEN1, PLpro core,
and SENP2 catalytic core were generated as previously described (Nicholson
et al., 2008). Amino terminal His6 tagged USP4, USP8, USP28, UCH-L1, UCH-
L3, UCH-L5, and MMP13 were expressed in Escherichia coli. N-terminal His6
tagged USP15, USP20, and USP47 were expressed in Sf9 cells. All the re-
combinant proteins were purified by chromatography. Amino terminal tagged
His6 Ub-PLA2 (Ub-CHOP), SUMO3-PLA2 (SUMO3-CHOP), ISG15-PLA2
(ISG15-CHOP), NEDD8-PLA2 (NEDD8-CHOP), Ub-EKL (Ub-CHOP2), and
free catalytically active PLA2 were prepared as described (Nicholson et al.,
2008; Tian et al., 2011).
Activity Based Profiling of DUB Inhibitors in Crude Extracts
and Living Cells
The labeling of endogenous active DUBs in crude cell extracts using the active
site molecular probes HA-UbVME and HA-UbBr2 was performed essentially
as described (Borodovsky et al., 2002) and further described in the Supple-
mental Information.
Isolation of Ubiquitylated Proteins
For the isolation of polyubiquitylated material from control or cells treated with
DUB inhibitors (as indicated), crude cell extracts were prepared as described
above with the addition of 35 mg GST-TUBE 1 or 2 (Lifesensors) to the lysate
material (400 mg). After incubation on ice for 15 min, polyubiquitylated material
was immunoprecipitated for 2 hr using glutathione affinity resin (Sigma-
Aldrich) washed in TBS containing 0.1% NP40 and eluted using TBS contain-
ing 10 mM reduced glutathione (Sigma-Aldrich). Proteins were chloroform/
methanol precipitated and kept at 80C for further processing, either by
in-solution digest (90%, see below) or resuspension in SDS-sample buffer
(10%), separation by Bis-Tris 4%–12% SDS-PAGE, and analysis by anti-ubiq-
uitin immunoblotting.
Sample Preparation and Analysis by Tandem Mass Spectrometry
Samples were subjected to in-solution trypsin digestion as described (Xu et al.,
2008), and the analysis by tandem mass spectrometry (LC-MS/MS) is
described in Supplemental Experimental Procedures.
Analysis of HDM2/p53/p21 and Claspin/pChk1Ser317
These experiments are described in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
doi:10.1016/j.chembiol.2011.08.018.
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